Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Iclusig ponatinib: Phase II started

September 28, 2015 7:00 AM UTC

Ariad began the open-label, international Phase II OPTIC trial to evaluate 15, 30 and 45 mg oral Iclusig once daily in about 450 patients who are resistant to >=2 approved TKIs. Patients in the 2 higher dose arms will have their dose reduced to 15 mg upon achievement of MyCyR. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article